Cognition Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



IPO | Alive

Total Raised


About Cognition Therapeutics

Cognition Therapeutics is a clinical-stage biopharmaceutical company that develops small-molecule therapeutics that address the toxic oligomeric proteins that cause synapse degeneration and trigger neurodegenerative conditions such as Alzheimer's disease.

Cognition Therapeutics Headquarter Location

2403 Sidney Street Suite 261

Pittsburgh, Pennsylvania, 15203,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cognition Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cognition Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Cognition Therapeutics Patents

Cognition Therapeutics has filed 16 patents.

The 3 most popular patent topics include:

  • Neurological disorders
  • Clusters of differentiation
  • Acetylcholinesterase inhibitors
patents chart

Application Date

Grant Date


Related Topics




Neurological disorders, Alzheimer's disease, Clusters of differentiation, Cognitive disorders, Rare diseases


Application Date


Grant Date



Related Topics

Neurological disorders, Alzheimer's disease, Clusters of differentiation, Cognitive disorders, Rare diseases



Latest Cognition Therapeutics News

Cognition Therapeutics to Participate in H.C. Wainwright Global Investment Conference

May 13, 2022

05/13/2022 | 07:31am EDT Message : *Required fields PURCHASE, N.Y., May 13, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina (the “Company” or “Cognition”), today announced that Lisa Ricciardi , the Company’s president and CEO and Mary Hamby, Ph.D., vice president of research, will be presenting at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Miami Beach Hotel from May 23-26, 2022. A live and archived webcast will be available on the  H.C. Wainwright meeting platform and on the Investors section of the company’s website at . In addition, Ms. Ricciardi and Dr. Hamby will be available for one-on-one meetings during the conference. Registered investors will be able to request a meeting with management via the conference portal. Details of the event are as follows: Presentation date: May 25, 2022 Time: 3:30 p.m. EDT About Cognition Therapeutics, Inc. Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at . Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and are available at You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact Information:

Cognition Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cognition Therapeutics Rank

  • When was Cognition Therapeutics founded?

    Cognition Therapeutics was founded in 2007.

  • Where is Cognition Therapeutics's headquarters?

    Cognition Therapeutics's headquarters is located at 2403 Sidney Street, Pittsburgh.

  • What is Cognition Therapeutics's latest funding round?

    Cognition Therapeutics's latest funding round is IPO.

  • How much did Cognition Therapeutics raise?

    Cognition Therapeutics raised a total of $77.3M.

  • Who are Cognition Therapeutics's competitors?

    Competitors of Cognition Therapeutics include CellCentric, InterveXion Therapeutics, Arecor, Carmot Therapeutics, FORMA Therapeutics and 9 more.

You May Also Like

Active Pass Pharmaceuticals

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.

Transposagen Biopharmaceuticals

Transposagen Biopharmaceuticals produces genetically modified MutaRat Knockout Animal Models of human diseases for drug discovery and development. Per the company, the production of animal models is a $1.2 billion/year market and is expected to grow 12 percent annually through 2010.


NDRI aims to serve scientists with customized human biomaterials for use in studies to understand human disease and to develop drugs and therapies for treatments and cures. NDRI aims to make it easy for researchers to get the human tissues and organs they need, prepared, preserved and shipped precisely according to their specific scientific protocols.


Kalypsys is a drug discovery company using a cellular ultra high-throughput system to carry out massive drug screening in cellular models of human disease and toxicology.

InterveXion Therapeutics

InterveXion Therapeutics is a drug discovery and development company focused on antibody-based therapies for treating human disease. The company are developing monoclonal antibodies to treat substance abuse from PCP and methamphetamine.

Echelon Biosciences Logo
Echelon Biosciences

Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brain development, immunological competence and the regulation of blood pressure. Both LPA and autotaxin have also been implicated in numerous diseases, especially metastatic cancer. Autotaxin was identified as one of the 40 most induced genes in aggressive breast cancer. The broader impacts of this research are the discovery and commercialization of tools that easily highlight specific biological pathways in living organisms. ATXRed will be welcomed by basic researchers in many fields associated with autotaxin and LPA. However, the utility extends beyond the basic research sphere. ATXRed smart probes could also aid pharmaceutical researchers searching for pharmacological inhibitors of autotaxin and LPA receptor agonists and antagonists. ATXRed would be a powerful tool in many rodent models of human cancer. In vivo autotaxin imaging probes could also aid in the clinic by helping to identify and monitor disease progression and treatment. Ultimately, ATXRed could help guide surgical resection of tumorstumors previously identified by the smart probe to have elevated autotaxin activity. In total, ATXRed probes have the potential to impact basic research, drug discovery and the clinic as a prime example of molecular medicine applied from bench to bedside.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.